Sobi rises as it reports 2nd-qtr results
Swedish Orphan Biovitrum (STO: SOBI) today released financial results covering the second quarter of 2022, showing that revenues came in at 3,876 million kronor ($369 million), a rise of 21% (+10% at constant exchange rates). Shares of the firm, also known as Sobi, were up 4.2% at 227.00 kronor by early afternoon trading.
Earnings before interest, taxes and amortization (EBITA) rose 2.4% to 922 million kronor. Earnings per share (EPS) were 0.91 kronor, versus 0.91 kroner in the like year-earlier period. EPS before dilution adjusted was unchanged at 0.91 kronor. Cash flow from operating activities was 423 million kronor compared to 1,393 million kronor in second-quarter 2021.
2022 outlook
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze